scleroderma
SCLERODERMA
Scleroderma is a connective tissue disorder characterized by skin thickening and fibrosis. It is rare, autoimmune and chronic.
It has an idiopathic cause and not contagious.
Early microvascular damage, mononuclear cell infiltrates and slowly developing fibrosis are the important features of the tissue lesions.
The leading causes of death are pulmonary fibrosis and pulmonary arterial hypertension.

Scleroderma References

  1. MedWorm http://www.medworm.com/rss/index.php/Dermatology/12/ http://www.medworm.com/rss/medicalfeeds/specialities/Dermatology-News.xml
  2. Denton C. Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults. UpToDate. https://www.uptodate.com. 20 Nov 2019.
  3. Denton C. Immunomodulatory and antifibrotic approaches to the treatment of systemic sclerosis (scleroderma). UpToDate. http://www.uptodate.com/contents/immunomodulatory-and-antifibrotic-approaches-to-the-treatment-of-systemic-sclerosis-scleroderma. Jul 2013.
  4. Denton C. Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults. UpToDate. http://www.uptodate.com/contents/overview-of-the-treatment-and-prognosis-of-systemic-sclerosis-scleroderma-in-adults. Oct 2013.
  5. Jacobe H. Treatment of morphea (localized scleroderma) in adults. UpToDate. https://www.uptodate.com. 16 Apr 2018.
  6. American College of Rheumatology. Localized scleroderma. American College of Rheumatology. https://www.rheumatology.org/Practice/Clinical/Patients/Diseases_And_Conditions/Localized_Scleroderma_(Juvenile)/. Jun 2012.
  7. American College of Rheumatology. Scleroderma (also known as systemic sclerosis). American College of Rheumatology. http://www.rheumatology.org/practice/clinical/patients/diseases_and_conditions/scleroderma.asp. Feb 2013.
  8. Arthritis Foundation of Malaysia. Scleroderma. Arthritis Foundation of Malaysia. http://www.afm.org.my/info/scleroderma.htm.
  9. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013 Nov;72(11):1747-1755. doi: 10.1136/annrheumdis-2013-204424.. PMID: 24092682
  10. Varga J. Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults. UpToDate. http://www.uptodate.com/contents/overview-of-the-clinical-manifestations-of-systemic-sclerosis-scleroderma-in-adults. Aug 2013.
  11. Varga J. Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults. UpToDate. http://www.uptodate.com/contents/diagnosis-and-differential-diagnosis-of-systemic-sclerosis-scleroderma-in-adults. Nov 2012.
  12. Fernández-Codina A, Walker KM, Pope JE; Scleroderma Algorithm Group. Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol. 2018 Nov;70(11):1820-1828. doi: 10.1002/art.40560. Accessed 13 Apr 2020. PMID: 29781586
  13. Hopkins W, Rubin LJ. Treatment of pulmonary arterial hypertension (group 1) in adults: pulmonary hypertension-specific therapy. UpToDate. https://www.uptodate.com. 28 Jan 2020.
  14. Wigley FM. Treatment of Raynaud phenomenon: initial management. UpToDate. https://www.uptodate.com. 13 Nov 2019.
  15. Wigley FM. Treatment of Raynaud phenomenon: refractory or progressive ischemia. UpToDate. https://www.uptodate.com. 18 Jul 2019.
  16. Weatherald J, Montani D, Jevnikar M, et al. Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev. 2019 Jul 31;28(153):pii: 190023. doi: 10.1183/16000617.0023-2019. PMID: 31366460
  17. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015 Oct;46(4):903-975. doi: 10.1183/13993003.01032-2015. PMID: 26318161
Editor's Recommendations
Most Read Articles
3 days ago
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 3 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
4 days ago
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.